Microbiota-targeted interventions for mental health Original paper

March 19, 2025

Last Updated: 2024-06-23

Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.

Karen Pendergrass

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

What was reviewed?

This review examined recent advances in microbiota-targeted interventions for the management of mental health. It focused on a variety of approaches that target the gut microbiota, including probiotics, prebiotics, synbiotics, fecal microbiota transplants (FMT), postbiotics, microbial metabolites, whole dietary interventions, and fermented foods. The review aimed to update the current understanding of how these interventions can influence mental health and to identify gaps in the existing literature.

Who was reviewed?

The review synthesized findings from studies involving both healthy populations and clinical cohorts with mental health disorders such as depression and anxiety. It included evidence from preclinical animal models as well as human clinical trials, emphasizing studies that explored the impact of gut microbiota modulation on mental health outcomes.

What were the most important findings of this review?

Probiotics: Probiotic supplementation, particularly using strains of bifidobacteria and lactobacilli, has shown promise in reducing stress, anxiety, and depressive symptoms. However, the evidence is mixed, and more randomized controlled trials (RCTs) in clinical populations are needed. Multistrain probiotics and combined dietary-probiotic approaches appear to enhance efficacy.

Prebiotics: Prebiotics have demonstrated potential benefits for mental health, though the evidence is less robust compared to probiotics. The impact of prebiotics like galactooligosaccharides (GOS) varies based on the population and specific mental health conditions studied.

Synbiotics: Combining probiotics and prebiotics (synbiotics) has shown positive outcomes in improving mood and reducing stress and anxiety in specific populations, but research is still in early stages.

Postbiotics and Microbial Metabolites: These emerging interventions show potential for modulating brain function and behavior, but human studies are limited. Some microbial metabolites, such as short-chain fatty acids (SCFAs), have shown promising effects in animal models and preliminary human studies.

Fecal Microbial Transplant (FMT): FMT presents a promising but nascent approach for treating psychiatric disorders. Preliminary animal and small human studies suggest benefits, but larger, well-controlled trials are necessary.

Whole Dietary Interventions: Diets like the Mediterranean and Japanese diets, high in fiber and fermented foods, have been associated with better mental health outcomes. However, evidence from large human cohorts is limited, and individualized dietary responses need further investigation.

Fermented Foods: These have been traditionally consumed for their health benefits, and recent studies suggest they may positively impact mental health. However, evidence is still sparse and inconclusive.

What are the greatest implications of this review?

Promising Adjunct Therapies: The review highlights the potential of microbiota-targeted interventions as adjunct therapies for mental health disorders. These approaches could complement existing pharmacological treatments, offering new avenues for patients who do not respond well to conventional medications.

Personalized Medicine: The personalized nature of gut-targeted interventions is emphasized. Factors such as baseline microbiota composition, dietary habits, and individual microbiota profiles will be crucial in tailoring effective treatments. This underscores the need for personalized medicine approaches in developing microbiota-targeted therapies.

Need for High-Quality Research: There is a significant need for large, well-designed clinical trials to establish the efficacy and safety of these interventions. Future research should focus on well-characterized clinical populations, standardized dosages, and intervention durations to develop evidence-based guidelines.

Long-Term Interventions: The potential for long-term changes in the microbiota through diet and other interventions suggests that many of these approaches may need to be sustained over the long term to maintain benefits.

Mechanistic Insights: Understanding the specific mechanisms through which microbiota-targeted interventions influence brain function and behavior will be crucial. This includes studying microbial metabolites and their interactions with the host’s nervous system.

Broader Implications for Health: Given the bidirectional relationship between the gut microbiota and the brain, these interventions may have broader implications for overall health, influencing not just mental health but also systemic conditions related to the gut-brain axis.

Fecal Microbiota Transplantation (FMT)

Fecal Microbiota Transplantation (FMT) involves transferring fecal bacteria from a healthy donor to a patient to restore microbiome balance.

Join the Roundtable

Contribute to published consensus reports, connect with top clinicians and researchers, and receive exclusive invitations to roundtable conferences.